[ET Net News Agency, 28 December 2021] SSY Group Limited (02005) said the group's
Ipratropium Bromide has obtained the approval for registration from the National Medical
Products Administration of China to become a bulk drug for the preparations on the market.
Ipratropium Bromide is a type of bronchodilator, which is mainly used for the treatment
of chronic obstructive pulmonary disease and asthma. (RC)